What Is Wegovy HD?
In March 2026, the FDA approved Wegovy HD — a 7.2mg injectable dose of semaglutide that's triple the standard 2.4mg maintenance dose. It's the strongest FDA-approved semaglutide formulation ever, and it's designed for patients who've hit a plateau on the standard dose and need additional weight loss.
Clinical trials showed Wegovy HD produced significantly greater weight reduction than the 2.4mg dose in patients who had already been on standard Wegovy for at least 4 weeks. Novo Nordisk expects it to be available in pharmacies by April 2026.
Pricing Status
Wegovy HD pricing has not been officially announced as of March 2026. Based on Novo Nordisk's existing pricing structure, we project it will fall in the $349–$499/mo range for self-pay patients.
What We Know About Pricing
Novo Nordisk has stated that pricing and coverage information will be available when Wegovy HD reaches pharmacies, expected April 2026. In the meantime, here's what we can project based on the existing Wegovy pricing framework:
Self-pay through NovoCare: The current Wegovy injection self-pay price is $349/month at maintenance doses. Wegovy HD will likely be priced at or slightly above this level — potentially $349–$499/month — since Novo Nordisk has been aggressive about competitive pricing in 2026.
With insurance + savings card: If your commercial insurance covers Wegovy, the savings card should apply to Wegovy HD as well, potentially bringing costs to $25–$150/month depending on your plan's cost-sharing structure.
Medicare (starting July 2026): The Medicare bridge program caps GLP-1 copays at $50/month. If Wegovy HD is available by July, it should qualify under the same program.
Who Is Wegovy HD For?
Wegovy HD is specifically approved for adults with obesity who have been tolerating the 2.4mg dose for at least 4 weeks and need additional weight loss. It's not a starting dose — you titrate up through the standard Wegovy doses first.
The typical path looks like this: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg → 7.2mg (HD). Including titration, reaching the HD dose takes approximately 5–6 months.
This matters for cost planning. Your first 5–6 months will be at standard Wegovy pricing. The HD premium (if any) only kicks in once you reach the 7.2mg dose.
Wegovy HD vs. Other Options: What's the Better Value?
Before committing to Wegovy HD, consider whether switching medications might achieve similar results at lower cost:
| Option | Est. Monthly Cost | Avg. Weight Loss | Status |
|---|---|---|---|
| Wegovy HD (7.2mg sema) | $349–$499/mo (projected) | Higher than 2.4mg (exact TBD) | Available ~Apr 2026 |
| Zepbound (tirzepatide) | $299–$449/mo | ~20–21% body weight | Available now |
| Compounded tirzepatide | $258–$400/mo | ~20–21% (based on brand trials) | Available (w/ eligibility) |
| Standard Wegovy (2.4mg) | $149–$349/mo | ~15% body weight | Available now |
Here's the key question: if you've plateaued on standard-dose semaglutide (2.4mg), switching to tirzepatide (Zepbound or compounded) might produce better results than a higher dose of the same drug — and potentially at a lower price point.
Discuss both options with your provider. Some patients respond better to higher-dose semaglutide, while others benefit from the dual-agonist mechanism of tirzepatide.
Sesame Care — FDA-Approved Medications
Real video visits with licensed providers. Access brand-name Wegovy, Ozempic, and Zepbound with manufacturer savings programs.
See Options →Sponsored
Current Alternatives While You Wait
If you're on standard Wegovy and want more aggressive weight loss now — before Wegovy HD hits pharmacies — compounded options offer flexibility:
Synergy Rx — From $200/mo
All-inclusive compounded semaglutide. No hidden fees — consultation, medication, and shipping bundled into one price.
Check Availability →Sponsored · Compounded medications are not FDA-approved.
SHED — From $199/mo
Compounded semaglutide and tirzepatide with a 10% weight-loss guarantee. Choose injectable, drops, or lozenges. FSA/HSA accepted.
Check Availability →Sponsored · Compounded medications are not FDA-approved.
The Bottom Line
Wegovy HD is a significant development for patients who've maxed out on standard semaglutide dosing. Official pricing is expected in April 2026, and we project it will be in the $349–$499/month range for self-pay patients — competitive with tirzepatide options.
We'll update this page with confirmed pricing as soon as Novo Nordisk announces it. In the meantime, compare all current options on our master pricing table.